SELLAS Life Sciences Group, Inc. (SLS) Financial Statements (2023 and Earlier)

Company Profile

Business Address 7 TIMES SQUARE
NEW YORK, NY 10036
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21,35535,3027,2775,3372,31918,08329,730
Cash and cash equivalents21,35535,3027,2775,3372,31918,08329,730
Restricted cash and investments10010010011410,43118,022401
Receivables      21,700
Prepaid expense244251284    
Capitalized contract cost 1,128  
Disposal group, including discontinued operation     813392
Other undisclosed current assets1,3451445813873375811,398
Total current assets:23,04436,9258,2425,83813,08737,49953,621
Noncurrent Assets
Operating lease, right-of-use asset723896217
Property, plant and equipment     199335
Intangible assets, net (including goodwill)1,9141,9141,9141,91419,5145,8985,898
Goodwill1,9141,9141,9141,9141,9145,8985,898
Intangible assets, net (excluding goodwill)    17,600  
Regulated entity, other noncurrent assets      (485)
Deposits noncurrent assets59461453666392596171
Deferred tax assets, net  (5,661)(5,418)
Other undisclosed noncurrent assets 5,7005,7008,500 27,78028,022
Total noncurrent assets:3,2319,1248,36711,07720,43928,31228,523
TOTAL ASSETS:26,27546,04916,60916,91533,52665,81182,144
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,7846,5705,0735,97414,8925,1326,889
Accounts payable2,1444,6573,9023,75511,6918401,597
Accrued liabilities2,6401,9131,1712,2193,2014,2925,292
Deferred revenue 5,600 
Debt  217 8,37716,3974,739
Estimated litigation liability    1,30095025,000
Disposal group, including discontinued operation     6,0595,925
Other undisclosed current liabilities198166   1,86014,518
Total current liabilities:4,98212,3365,2905,97424,56930,39857,071
Noncurrent Liabilities
Long-term debt and lease obligation610825  2,611  
Long-term debt, excluding current maturities    2,611  
Operating lease, liability610825 
Liabilities, other than long-term debt 239262 1,673  
Deferred tax liabilities, net 1,673  
Deferred income tax liabilities 239262
Other undisclosed noncurrent liabilities(274)4,6884,9645,6962,6036,75611,560
Total noncurrent liabilities:9465,7525,2265,6966,8876,75611,560
Total liabilities:5,92818,08810,51611,67031,45637,15468,631
Stockholders' equity
Stockholders' equity attributable to parent, including:20,34727,9616,0935,2452,07028,65713,513
Common stock215211515
Treasury stock, value     (3,849)(3,849)
Additional paid in capital158,948145,864107,23587,09856,254335,423296,730
Accumulated deficit(138,603)(117,904)(101,147)(81,855)(54,185)  
Other undisclosed stockholders' equity attributable to parent     (302,932)(279,383)
Total stockholders' equity:20,34727,9616,0935,2452,07028,65713,513
TOTAL LIABILITIES AND EQUITY:26,27546,04916,60916,91533,52665,81182,144

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues7,6001,900     
Cost of revenue(200) (20,041)(31,089)(5,200)  
Cost of goods and services sold(200)   (5,200)  
Gross profit:7,4001,900(20,041)(31,089)(5,200)  
Operating expenses(32,694)(18,882)  (23,039)(31,867)(34,220)
Other undisclosed operating income    5,200  
Operating loss:(25,294)(16,982)(20,041)(31,089)(23,039)(31,867)(34,220)
Nonoperating income (expense)4,358208(19,373)(29,048) 21,009(4,371)
Other nonoperating income 208   5,047509
Interest and debt expense   766 3,054 
Other undisclosed loss from continuing operations before equity method investments, income taxes     (3,054) 
Loss from continuing operations before equity method investments, income taxes:(20,936)(16,774)(39,414)(59,371)(23,039)(10,858)(38,591)
Other undisclosed income (loss) from continuing operations before income taxes  20,04230,323(462)  
Loss from continuing operations before income taxes:(20,936)(16,774)(19,372)(29,048)(23,501)(10,858)(38,591)
Income tax expense (benefit)23717811,378(253)(243)(365)
Other undisclosed loss from continuing operations  (1)    
Net loss:(20,699)(16,757)(19,292)(27,670)(23,754)(11,101)(38,956)
Other undisclosed net loss attributable to parent     (12,448)(24,946)
Net loss attributable to parent:(20,699)(16,757)(19,292)(27,670)(23,754)(23,549)(63,902)
Preferred stock dividends and other adjustments   (4,436)   
Other undisclosed net loss available to common stockholders, basic (78)(8,659)(9,145)(675)  
Net loss available to common stockholders, diluted:(20,699)(16,835)(27,951)(41,251)(24,429)(23,549)(63,902)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(20,699)(16,757)(19,292)(27,670)(23,754)(11,101)(38,956)
Other comprehensive loss      (63,902)
Comprehensive loss, net of tax, attributable to parent:(20,699)(16,757)(19,292)(27,670)(23,754)(11,101)(102,858)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: